PA mifepristone

The PA mifepristone also delays or inhibits ovulation, which may produce amenorrhea [48, 49]. Amenorrhea may be a consequence of an effect at the level of the ovary, pituitary or hypothalamus. The SPRM asoprisnil, in contrast, is not so effective in inhibiting ovulation [50]. The amenorrhea consequent to PAs and SPRMs occurs with levels of estradiol in the range of the early follicular phase of the menstrual cycle [48-50]. As a result ofthe antiproliferative effect and the amenorrhea, PAs and SPRMs have been advocated in the treatment of uterine myoma, endometriosis and dysfunctional uterine bleeding. 

---